Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Seer (Nasdaq: SEER) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The life sciences company, which specializes in proteomics platform technology, will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast through the Investor section of Seer's website at investor.seer.bio, where an archived replay will also be available after the event.
Seer (Nasdaq: SEER) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 giovedì 27 febbraio 2025. L'azienda delle scienze della vita, specializzata nella tecnologia delle piattaforme proteomiche, ospiterà una conferenza telefonica e un webcast alle 13:30 ora del Pacifico / 16:30 ora dell'Est nello stesso giorno. Gli investitori possono accedere al webcast dal vivo attraverso la sezione Investor del sito web di Seer su investor.seer.bio, dove sarà disponibile anche una registrazione archiviata dopo l'evento.
Seer (Nasdaq: SEER) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 el jueves 27 de febrero de 2025. La empresa de ciencias de la vida, especializada en tecnología de plataformas de proteómica, llevará a cabo una llamada de conferencia y una transmisión web a la 1:30 p.m. hora del Pacífico / 4:30 p.m. hora del Este el mismo día. Los inversores pueden acceder a la transmisión en vivo a través de la sección de inversores del sitio web de Seer en investor.seer.bio, donde también estará disponible una repetición archivada después del evento.
Seer (Nasdaq: SEER)는 2025년 2월 27일 목요일에 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다. 단백질체학 플랫폼 기술을 전문으로 하는 생명 과학 회사는 같은 날 태평양 표준시 오후 1:30 / 동부 표준시 오후 4:30에 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다. 투자자들은 Seer의 웹사이트 투자자 섹션인 investor.seer.bio를 통해 라이브 웹캐스트에 접속할 수 있으며, 이벤트 후 아카이브된 재생도 이용할 수 있습니다.
Seer (Nasdaq: SEER) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 le jeudi 27 février 2025. L'entreprise de sciences de la vie, spécialisée dans la technologie des plateformes de protéomique, organisera une conférence téléphonique et un webinaire le même jour à 13h30 heure du Pacifique / 16h30 heure de l'Est. Les investisseurs peuvent accéder au webinaire en direct via la section Investisseurs du site Web de Seer à l'adresse investor.seer.bio, où une rediffusion archivée sera également disponible après l'événement.
Seer (Nasdaq: SEER) hat angekündigt, dass es am Donnerstag, den 27. Februar 2025, seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlichen wird. Das Unternehmen für Lebenswissenschaften, das sich auf Proteomik-Plattformtechnologie spezialisiert hat, wird am selben Tag um 13:30 Uhr Pazifischer Zeit / 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über den Investor-Bereich der Website von Seer unter investor.seer.bio auf den Live-Webcast zugreifen, wo nach der Veranstaltung auch eine archivierte Wiederholung verfügbar sein wird.
- None.
- None.
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
When will Seer (SEER) release its Q4 and full year 2024 earnings?
What time is Seer's Q4 2024 earnings call?
Where can I listen to Seer's Q4 2024 earnings webcast?
Will Seer's Q4 2024 earnings call be available for replay?
